36 -12 (74) 2024 - Naimova Sh.A. - CLINICAL CHARACTERISTICS OF ANEMIA WITH CKD IN RA PATIENTS

CLINICAL CHARACTERISTICS OF ANEMIA WITH CKD IN RA PATIENTS

Naimova Sh.A. - Bukhara State Medical Institute named after Abu Ali ibn Sina

Resume

The purpose of this work is to systematize modern data on the pathogenetic mechanisms of anemia development in patients with RA and CKD, as well as to determine the role of each disease in the formation of this complication. Anemia is a common complication of both rheumatoid arthritis (RA) and chronic kidney disease (CKD). The combination of these two diseases significantly worsens the clinical picture and reduces the patient's quality of life. The combination of rheumatoid arthritis (RA) and chronic kidney disease (CKD) significantly complicates the clinical picture and significantly increases the risk of anemia. This review aims to examine in detail the pathogenetic mechanisms underlying the development of anemia in this complex disease.

Keywords: rheumatoid arthritis, chronic kidney disease, anemia, pathogenesis, treatment.

First page

196

Last page

201

For citation:Naimova Sh.A. - CLINICAL CHARACTERISTICS OF ANEMIA WITH CKD IN RA PATIENTS //New Day in Medicine 12(74)2024 196-201 https://https://newdayworldmedicine.com/en/new_day_medicine/12-74-2024

List of References

  1. Abhishek A, Doherty M, Kuo CF, Mallen CD, Zhang W, Grainge MJ. Rheumatoid arthritis is getting less frequentdresults of a nationwide population-based cohort study. //Rheumatology 2017;56:736-44.
  2. Aggarwal P. Renal involvement in rheumatoid arthritis: a case report and review of literature / P. Aggarwal, A. Aggarwal, S. Dhingira, R. Misra //J.Indian Reumatol. 2004;12:70-73.
  3. Berthoux F.C. Natural history of primary IgA nephropathy / F.C. Berthoux, H. Mohey, A. Afiani //Semin. Nephrol. 2008;1:4-9.
  4. Combe B, Landewe R, Daien CI, Hua C, Aletaha D, AlvaroGracia JM, et al. 2016 update of the EULAR recommendations for the management of early arthritis. //Ann Rheum Dis 2017;76:948e59.
  5. Deane KD, Holers VM. Rheumatoid arthritis pathogenesis, prediction, and prevention: an emerging paradigm shift. //Arthritis Rheumatol 2021;73:181-93.
  6. Hezemans R.L. Dialysis treatment in patients with rheumatoid arthritis /R.L. Hezemans, R.T. Krediet, L. Arisz //Neth. J. Med. 1995;47:6-11.
  7. Hickson LJ, Crowson CS, Gabriel SE, McCarthy JT, Matteson EL. Development of reduced kidney function in rheumatoid arthritis. //Am J Kidney Dis. 2014;63(2):206-213
  8. Schodel P.J. Ratcliffe Mechanisms of hypoxia signalling: new implications for nephrology Nat Rev Nephrol, 2019;15:641-659.
  9. Babitt J.L., Eisenga M.F., Haase V.H. et al. Controversies in optimal anemia management: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Conference Kidney Int, 2021;99:1280-1295.
  10. Julian B.A. Treatment of IgA nephropathy / B.A. Julian //Semin. Nephrol. 2000;20(3):277-285.
  11. Karstila K, Korpela M, Sihvonen S, Mustonen J. Prognosis of clinical renal disease and incidence of new renal findings in patients with rheumatoid arthritis: follow-up of a population-based study. //Clin Rheumatol. 2007;26(12):2089-2095.
  12. Kidney Disease: Improving Global Outcomes (KDIGO) Anemia Work Group KDIGO Clinical Practice Guideline for Anemia in Chronic Kidney Disease Kidney Int Suppl, 2012;2:279-335.
  13. Mori S, Yoshitama T, Hirakata N, Ueki Y. Prevalence of and factors associated with renal dysfunction in rheumatoid arthritis patients: a cross-sectional study in community hospitals. //Clin Rheumatol 2017;36:2673-82.
  14. Nagy J. Renal protection in IgA nephropathy requires strict blood pressure control / J. Nagy, I. Wittmann //Nephrology Dialysis Transplantation. 2005;20(8):1533-1539.
  15. Safiri S, Kolahi AA, Hoy D, Smith E, Bettampadi D, Mansournia MA, et al. Global, regional and national burden of rheumatoid arthritis 1990e2017: a systematic analysis of the Global Burden of Disease study 2017. //Ann Rheum Dis 2019;78:1463-71.
  16. Haase V.H. Hypoxia-inducible factor-prolyl hydroxylase inhibitors in the treatment of anemia of chronic kidney disease Kidney Int Suppl (2011). 2021:11:8-25.
  17. Wakblu A., Krisnani N., Hisoriya P. ва бошқ., 2003 (Wakblu A. Prevalence of secondary amyloidosis in Asian North Indian patients with rheumatoid arthritis / A. Wakblu, N. Krisnani, P. Hissaria, A. Aggarwal, R. Misra //Journal of Rheumatolog. 2003;30(5):948-951.
  18. Алиахунова М.Ю., Наимова Ш.А. Features of kidney damage at patients with rheumatoid arthritis //Новый день в медицине. 2020;2(30):47-49.
  19. Думан В.Л. Факторы, влияющие на прогноз при хроническом гломерулонефрите с изолированным мочевым синдромом /В.Л. Думан, Н.Ю. Батанина //Госпитальный вестник. 2005;3:42-47.
  20. Наимова Ш.А., Рузиева Ф.А. Особенности почечной коморбидности при ревматологических заболеваниях //Вестник науки и образования. 2020;24/2(102):74-78.

    file

    download